Market Research Logo

Global Neurological Biomarkers Market 2016-2020

Global Neurological Biomarkers Market 2016-2020

About Biomarkers

Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers.

Technavio’s analysts forecast the global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global neurological biomarkers market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of neurological biomarkers.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Neurological Biomarkers Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Myriad RBM
  • Proteome Sciences
  • QIAGEN
  • Thermo Fisher Scientific
Other prominent vendors
  • AbaStar MDx
  • Abiant
  • Acumen Pharmaceuticals
  • Aepodia
  • Alseres Pharmaceuticals
  • Athena Diagnostics
  • Banyan Biomarkers
  • Cisbio Bioassays
  • Diagenic
  • Proteosys
  • Psynova Neurotech
Market driver
  • Increasing focus toward drug discovery applications
  • For a full, detailed list, view our report
Market challenge
  • Unmet market needs of effective validation of biomarkers
  • For a full, detailed list, view our report
Market trend
  • Integrated biology approach will be the key focus area
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Neurological Biomarkers Market 2016-2020

Technavio recognizes the following companies as the key players in the global neurological biomarkers market: Myriad RBM, Proteome Sciences, QIAGEN, and Thermo Fisher Scientific.

Other Prominent Vendors in the market are: AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, and Psynova Neurotech.

Commenting on the report, an analyst from Technavio’s team said: “Integrated biology approach will be the key focus area and a key trend for market growth. Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area.”

According to the report, one of the key drivers for market growth will be increasing focus toward drug discovery applications. Close to 1% of medications in the biomarker discovery and development pipeline achieve the commercial success. The rate of failure cases is too high, and very frequently drug candidates fail in the late development phase. This has led to the evolution of alternative biomarker-based techniques by contract research organizations and manufacturers.

Further, the report states that unmet market needs will be a challenge for the market. The inability to give convincing proof regarding the clinical and financial advantages of introducing new biomarker-based diagnosis methods are recognized as the main challenge for moderate uptake of new biomarkers. Genuine limitations, such as reproduction of positive clinical trial result, the absence of early pre-analytical examinations, the absence of autonomous check of results, and failure of investigators to assess whether the use of the biomarker would improve clinical practice to the benefit of neuro patients are hindering diagnostic neurological biomarker validation. Innovative evaluation of fluid-based proteomics enables biomarkers identification as indicators of the onset of neurological disease have been complex and incurs high research cost.

Companies Mentioned

Myriad RBM, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, Psynova Neurotech.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Biomarker assays kits
  • Market landscape
    • Market overview
      • Table Key biomarker technology platforms
    • Market size and forecast
      • Table Global neurological biomarkers market (2016-2020) ($ billions)
    • Five forces analysis:
      • Table Five forces analysis
  • Market segmentation by indication
    • Table Market segmentation by indication
    • AD
    • PD
    • ASD
    • MS
      • Table Market opportunities in the major indications
  • Market segmentation by application
    • Table Global neurological biomarkers market segmentation by application 2015
    • Genomics-based biomarkers
    • Proteomics-based biomarkers
    • Metabolomics-based biomarkers
    • Imaging-based biomarkers
    • Emerging application areas
      • Table Market opportunities in key applications
  • Market segmentation by services
    • Services
      • Table Impact mapping of neurological biomarker services
      • Table Opportunity analysis of biomarker services
  • Market segmentation by end-user
    • Hospitals
    • Diagnostic and research laboratories
  • Geographical segmentation
    • Table Global neurological biomarkers market 2015
    • Neurological biomarkers market in Americas
      • Table Market overview in Americas 2015
      • Table Neurological biomarkers market in Americas ($ billions)
    • Neurological biomarkers market in EMEA
      • Table Market overview in EMEA 2015
      • Table Neurological biomarkers market in EMEA ($ billions)
    • Neurological biomarkers market in APAC
      • Table Market overview in APAC 2015
      • Table Neurological biomarkers market in APAC ($ millions)
  • Market drivers
    • Increasing low-cost clinical trials in developing countries
    • Growing personalized medicine for neurological disorders
    • Increasing focus toward drug discovery applications
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Unmet market needs of effective validation of biomarkers
    • Reproducibility of biomarkers and tests leading to discrepancies
    • Delay in market launch
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Integrated biology approach will be the key focus area
    • Development of novel radiotracers for neuro biomarkers that aid diagnostic and clinical applications for diseases
    • Evolution of miRNA
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global neurological biomarkers market 2015
      • Table Market penetration of key neurological biomarkers manufacturers 2015
      • Table Strategic success factors of companies in global neurological biomarkers market
  • Key vendor analysis
    • Geographic presence - Key vendor analysis
      • Table Regional analysis of key vendors
    • Myriad RBM
      • Table Myriad RBM: Profile
      • Table Myriad RBM: Strength analysis
      • Table Myriad RBM: Growth strategy matrix
      • Table Myriad RBM: Opportunity assessment analysis
    • Proteome Sciences
      • Table Proteome Sciences: Profile
      • Table Proteome Sciences: Strength analysis
      • Table Proteome Sciences: Growth strategy matrix
      • Table Proteome Sciences: Opportunity assessment
    • QIAGEN
      • Table QIAGEN: Profile
      • Table QIAGEN: Strength analysis
      • Table QIAGEN: Growth strategy matrix
      • Table QIAGEN: Opportunity assessment
    • Thermo Fisher Scientific
      • Table Thermo Fisher Scientific: Profile
      • Table Thermo Fisher Scientific: Strength analysis
      • Table Thermo Fisher Scientific: Growth strategy matrix
      • Table Thermo Fisher Scientific: Growth opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report